NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 7376D 
Neuropharm Group PLC 
08 December 2009 
 

+------------------------------------------+------------------------------------+ 
| For immediate release                    |                    8 December 2009 | 
+------------------------------------------+------------------------------------+ 
 
 
 
 
Neuropharm Group Plc 
("Neuropharm" or "the Company") 
 
 
 Continuing Discussions 
 
 
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on 
neurodevelopmental disorders, today provides an update to shareholders on 
developments in relation to the proposed sale or merger of the Company, as 
announced on 3 November 2009. 
Since the announcement, the Company has progressed discussions with an expanded 
number of third parties. Although discussions are at an early stage, the Board 
of Neuropharm continues to believe that shareholder value is more likely to be 
maximised through seeking a sale or merger partner which will be better placed 
to fund the Company's clinical development portfolio. 
A further update will be provided to shareholders in due course. 
 
 
 
 
For further information please contact: 
 
 
+-----------------------------------------------+--------------------+ 
| Neuropharm                                    |  + 44 (0) 1372 371 | 
|                                               |                171 | 
+-----------------------------------------------+--------------------+ 
| Robert Mansfield, Chief Executive Officer     |                    | 
| Graham Yeatman, Chief Financial Officer       |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Piper Jaffray Ltd.                            |   + 44 (0) 20 3142 | 
|                                               |               8700 | 
+-----------------------------------------------+--------------------+ 
| Neil Mackison, Rupert Winckler                |                    | 
+-----------------------------------------------+--------------------+ 
|                                               |                    | 
+-----------------------------------------------+--------------------+ 
| Buchanan Communications                       |   + 44 (0) 20 7466 | 
|                                               |               5000 | 
+-----------------------------------------------+--------------------+ 
| Mark Court                                    |                    | 
+-----------------------------------------------+--------------------+ 
 
 
 
 
Notes to Editors: 
 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
products for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
Piper Jaffray, which is authorised and regulated by the Financial Services 
Authority, is acting exclusively for Neuropharm and for no-one else in 
connection with the matters referred to in this announcement and will not be 
responsible to anyone other than Neuropharm for providing the protections 
afforded to customers of Piper Jaffray nor for giving advice in relation to the 
matters referred to in this announcement. 
 
 
Dealing Disclosure Requirements 
Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 
"Code"), if any person is, or becomes, "interested" (directly or indirectly) in 
1% or more of any class of "relevant securities" of Neuropharm, all "dealings" 
in any " relevant securities" of Neuropharm (including by means of an option in 
respect of, or a derivative referenced to, any such "relevant securities") must 
be publicly disclosed by no later than 3.30 pm (London time) on the London 
business day following the date of the relevant transaction. This requirement 
will continue until the date on which the offer becomes, or is declared, 
unconditional as to acceptances, lapses or is otherwise withdrawn or on which 
the "offer period" otherwise ends. If two or more persons act together pursuant 
to an agreement or understanding, whether formal or informal, to acquire an 
"interest" in "relevant securities" of Neuropharm, they will be deemed to be a 
single person for the purpose of Rule 8.3. 
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant 
securities" of Neuropharm by Neuropharm or by any of its "associates", must be 
disclosed by no later than 12.00 noon (London time) on the London business day 
following the date of the relevant transaction. 
A disclosure table, giving details of the companies in whose "relevant 
securities" "dealings" should be disclosed, and the number of such securities in 
issue, can be found on the Takeover Panel's website at 
www.thetakeoverpanel.org.uk. 
"Interests in securities" arise, in summary, when a person has long economic 
exposure, whether conditional or absolute, to changes in the price of 
securities. In particular, a person will be treated as having an "interest" by 
virtue of the ownership or control of securities, or by virtue of any option in 
respect of, or derivative referenced to, securities. 
Terms in quotation marks are defined in the Code, which can also be found on the 
Panel's website. If you are in any doubt as to whether or not you are required 
to disclose a "dealing" under Rule 8, you should consult the Panel. 
 
 
Rule 2.10 
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, the 
Company announces that it has 31,536,697 ordinary shares of 10 pence each in 
issue and admitted to trading on the AIM market of the London Stock 
Exchange plc. The International Securities Identification Number for the 
ordinary shares is GB00B1NPJJ01. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCCKOKQDBDBABK 
 

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Neuropharm (LSE:NPH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024